NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) news coverage focuses on its progress as a clinical-stage life sciences and biopharmaceutical company developing central nervous system therapeutics designed to overcome the blood-brain barrier. News releases frequently highlight updates from Phase 1/2a and Phase 2a clinical trials of intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma and other high-grade gliomas, as well as regulatory and operational milestones across its CNS oncology pipeline.
Investors following NTHI news can expect detailed reports on radiographic response rates, progression-free survival and long-term survival outcomes from NEO100 studies, along with safety and tolerability findings associated with prolonged intranasal dosing. Additional news items describe the advancement of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors, including U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb clinical development.
Company announcements also cover strategic partnerships and corporate developments, such as the establishment of the NuroMENA subsidiary in the United Arab Emirates, a Master Services Agreement with IROS (an M42-affiliated contract research organization), and share exchange or acquisition transactions disclosed in Form 8‑K filings. Updates on non-dilutive NIH STTR funding, intellectual property expansion, and NeOnc’s AI and 3D bioprinting initiatives for sonodynamic therapy research with NEO100 are also common themes.
By monitoring this NTHI news feed, readers can track NeOnc’s clinical data readouts, regulatory interactions, regional expansion efforts and financing-related disclosures as they are released through press announcements and SEC-referenced communications.
NeOnc Technologies Holdings (NTHI) priced a $15 million registered direct equity offering with institutional investors on September 9, 2026.
The company entered definitive agreements with new and existing healthcare-focused institutional investors to sell 3,571,430 shares of common stock, or pre-funded warrants in lieu thereof, plus accompanying warrants to purchase up to 3,571,430 shares. The combined purchase price is $4.20 per share and warrant, or $4.1999 per pre-funded warrant and warrant. Pre-funded warrants are exercisable immediately at $0.0001 per share and expire when fully exercised, while the accompanying warrants are immediately exercisable at $4.20 per share and expire five years from issuance.
Gross proceeds are estimated at approximately $15 million before fees and expenses, with closing expected on or about September 10, 2026, subject to customary conditions. The securities are offered under NeOnc’s effective Form S-3 shelf registration statement, with Roth Capital Partners and A.G.P./Alliance Global Partners acting as co-placement agents.
NeOnc Technologies (NTHI) reported positive topline Phase 2a data for NEO100 in recurrent or progressive Grade III/IV IDH1-mutant glioma and is planning a Type B FDA meeting to discuss a potential registrational pathway.
The study showed six-month progression-free survival of 48.9%, more than double the prespecified 20% benchmark, with a reported p-value of 0.0047. Median overall survival was 26.09 months, and 86.7% of patients were alive at six months. Five of 24 patients remained on treatment, including one partial response lasting beyond 114 days. NeOnc describes NEO100 as an intranasal, nose-to-brain formulation of purified perillyl alcohol aimed at aggressive gliomas where options are limited.
Beyond the U.S. program, NeOnc received UAE IND authorization for NEO100 across three adult trials and pediatric work, and NEO212 secured UAE IND clearance with a recommended Phase 2 dose of 610 mg. SEC filings show August insider share purchases by director Thomas Chen and CEO Amir Heshmatpour.
NeOnc Technologies Holdings (NASDAQ: NTHI) reported positive topline Phase 2a results for NEO100 in recurrent or progressive Grade III/IV IDH1‑mutant glioma, with six‑month progression‑free survival of 48.9%, substantially above the prespecified 20% benchmark (p=0.0047). Median overall survival was 26.09 months, and 86.7% of patients were alive at six months; five of 24 patients remained on treatment, including one ongoing partial response beyond 114 days.
According to NeOnc, these open‑label Phase 2a data achieved the primary endpoint and will support a planned request for a Type B FDA meeting to discuss a potential registrational pathway for NEO100. The company is also advancing NEO212, which has completed Phase 1 with a recommended Phase 2 dose of 610 mg, and has received UAE IND approvals for NEO100 and NEO212 across several adult and pediatric programs. Recent insider open‑market share purchases by the CEO and a director add to the backdrop as NeOnc remains a clinical‑stage biotech facing the usual development, regulatory and financing risks.
NeOnc Technologies Holdings (NASDAQ: NTHI) highlighted positive topline Phase 2a data for NEO100 in recurrent or progressive Grade III/IV IDH1‑mutant glioma. The study met its primary endpoint, with 48.9% six‑month progression‑free survival versus a prespecified 20% benchmark and a reported p‑value of 0.0047. Median overall survival was 26.09 months, with 86.7% of patients alive at six months; five of 24 patients remained on treatment, including one partial response beyond 114 days. NeOnc reported no major toxicities and predominantly low‑grade adverse events. The company plans to request a Type B FDA meeting to discuss a potential registrational pathway. NeOnc is also advancing NEO212, which completed Phase 1 with a recommended Phase 2 dose of 610 mg, and has obtained UAE IND approvals for NEO100 and NEO212. Insider purchases by the CEO and a board director followed the data, while Nasdaq reported 597,816 NTHI shares sold short as of August 14, 2026.
NeOnc Technologies (NASDAQ:NTHI) is drawing attention after CEO Amir Heshmatpour reported additional open‑market share purchases following a key clinical readout. Form 4 data show he bought 12,000 shares on August 14, 2026 at an average price of $3.7883 and 3,000 shares on August 17 at $4.3733, totaling 15,000 shares for about $58,600 at a roughly $3.91 weighted average. In April, NeOnc had disclosed that he purchased about $500,000 of NTHI stock.
According to NeOnc, NEO100’s Phase 2a study in recurrent IDH1‑mutant high‑grade glioma achieved six‑month progression‑free survival of 48.9% versus a 20% historical benchmark (p=0.0047), with median overall survival of 26.09 months and six‑, 12‑ and 24‑month overall survival rates of 86.7%, 60.9% and 54.1%. NEO100 already has FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations, and the company intends to seek a Type B FDA meeting on a potential registrational path. NeOnc also reports UAE IND authorization for multiple NEO100 protocols and completion of Phase 1 for NEO212 with a recommended Phase 2 dose of 610 mg. The article notes elevated short interest in NTHI, framing a setup that combines insider accumulation, clinical data and significant short positioning.
NeOnc Technologies Holdings (Nasdaq: NTHI) highlighted how its Nasdaq Global Market listing interacts with new Phase 2a data for lead candidate NEO100 in recurrent IDH1‑mutant high‑grade glioma. The company reported a six‑month progression‑free survival rate of 48.9% versus a 20% historical benchmark (p=0.0047), median overall survival of about 26.1 months, and six‑, 12‑ and 24‑month overall‑survival rates of approximately 86.7%, 60.9% and 54.1%, respectively, with no major toxicities reported.
According to NeOnc, the open‑label, single‑arm Phase 2a study provides an encouraging clinical signal but not definitive proof of efficacy, making a larger registrational trial and FDA discussions the next focus. The company emphasized its existing $75 million at‑the‑market equity facility with BTIG and A.G.P./Alliance Global Partners as a flexible financing tool, not cash already on the balance sheet. NeOnc also noted second‑quarter R&D expense of approximately $2.6 million, up from about $0.7 million a year earlier, and referenced additional pipeline work on NEO212 and UAE IND approvals for both NEO100 and NEO212.
NeOnc Technologies (NASDAQ: NTHI) received an updated coverage report highlighting stronger clinical and regulatory positioning in 2Q26. Lead asset NEO100 achieved its Phase 2a primary endpoint, with six‑month PFS of 48.9% by RANO 2.0 versus a 20% benchmark (p=0.0047), median OS of 26.09 months, and no major toxicities. The company plans to seek an FDA Type B meeting to discuss a potential registrational program. NEO212 advanced through Phase 2 CMC clearance and FDA feedback indicating a possible accelerated approval pathway. R&D expenses rose to $2.6M from $0.7M year over year, while management expands development into meningioma and pediatric brain tumors, noting that funding remains important as activity increases.
NeOnc Technologies (NASDAQ:NTHI) is highlighting its patented intranasal, nose‑to‑brain delivery platform built around NEO100, a purified perillyl alcohol formulation, following encouraging Phase 2a data in recurrent IDH1‑mutant high‑grade glioma.
According to NeOnc, its exclusive University of Southern California license spans 28 issued and 14 pending U.S. patents plus 65 issued and 28 pending international patents, covering NEO100, NEO212 and related assets, with claims that include intranasal, combination and other brain‑targeted delivery approaches. Preclinical work suggests intranasal NEO100 may help deliver other drugs, and a USC/NeOnc patent application addresses enhanced intranasal levodopa delivery.
The Phase 2a NEO100 study reported 48.9% six‑month PFS versus a 20% historical benchmark (p=0.0047), median overall survival of 26.09 months and 24‑month survival of 54.1%, with five of 24 patients still on treatment. NEO100 holds FDA Orphan Drug, Fast Track and Rare Pediatric Disease designations, and NeOnc plans to request a Type B FDA meeting on a registrational path. NEO212 has completed Phase 1 dose escalation with a recommended Phase 2 dose of 610 mg.
NeOnc Technologies Holdings (NASDAQ:NTHI) reported Phase 2a data for intranasal NEO100 in recurrent IDH1‑mutant high‑grade glioma. The study met its primary endpoint, with six‑month progression‑free survival of 48.9% versus a pre‑specified 20% benchmark (p=0.0047) in 24 patients.
According to the company, median overall survival was 26.09 months, with survival rates of 86.7% at six months, 60.9% at 12 months and 54.1% at 24 months. Five patients remained on treatment, including one progression‑free for about 19 months. Objective response rate by RANO 2.0 was 8.3% (two of 24 patients).
NeOnc reported no major toxicities, with predominantly low‑grade adverse events, and intranasal home administration four times daily in 28‑day cycles. Based on these early, open‑label data, the company plans to request an FDA Type B meeting to discuss a potential registrational development path.
NeOnc Technologies (Nasdaq:NTHI) reported positive topline Phase 2a data from NEO100-01, an open-label study of intranasal NEO100 in 24 patients with recurrent or progressive Grade III/IV IDH1‑mutant glioma who had failed radiation and temozolomide. The trial met its primary endpoint, with six‑month progression‑free survival of 48.9% (95% CI: 26.3‑68.1) by RANO 2.0 versus a pre‑specified 20% benchmark for standard of care (p=0.0047).
According to NeOnc, median overall survival was 26.09 months, with overall survival of 86.7% at six months, 60.9% at 12 months and 54.1% at 24 months. Five of 24 patients remain on therapy; two achieved objective responses (8.3%), including one ongoing partial response beyond 114 days. No major toxicities were reported, with predominantly low‑grade adverse events during long‑term, at‑home intranasal dosing. The company plans to request a Type B FDA meeting to discuss a registrational development path.